From previous preclinical findings continuous low dose (metronomic) chemotherapy is
thought to inhibit tumor angiogenesis. This suggests that activated endothelial cells may be …

Metronomic chemotherapy, which is continuously administered systemically at close to non‐
toxic doses, targets the endothelial cells (EC s) that are proliferating during tumor …

The anti-angiogenic activity of chemotherapy is both dose-and schedule-dependent. While
conventional maximum tolerated dose (MTD) chemotherapy exerts only mild and reversible …

In addition to proliferating cancer cells and various types of normal cells, such as those of
the bone marrow, conventional cytotoxic chemotherapeutics affect the endothelium of the …

New blood vessel formation is essential for the growth and metastasis of many cancers. As a
result, antitumor activities of various angiogenesis inhibitors have been intensely explored in …

Purpose Over the past few years, more and more new selective molecules directed against
specific cellular targets have become available for cancer therapy, leading to impressive …

Recent preclinical studies have shown that frequent administration in vivo of low doses of
chemotherapeutic drugs (“metronomic” dosing) can affect tumor endothelium and inhibit …

Low-dose metronomic chemotherapy is a promising therapeutic cancer treatment strategy
thought to have an antiangiogenic basis. However, the advantages of reduced toxicity …

The mechanism of action of anticancer chemotherapeutic agents is mainly thought to be due
to a direct inhibition of tumor cell proliferation. The enhanced endothelial cell proliferation …

Drug resistance and toxic side effects are major therapeutic hurdles affecting cancer patients
receiving conventional chemotherapy based on the maximum tolerated dose. Metronomic …